全球半固态製剂CDMO市场

预计到 2030 年，全球半固态剂型 CDMO 市场规模将达到 608 亿美元

全球半固态剂型CDMO市场规模预计在2024年为335亿美元，预计到2030年将达到608亿美元，2024年至2030年的复合年增长率为10.5%。外用剂型是本报告分析的细分市场之一，预计其复合年增长率为11.0%，到分析期结束时规模将达到365亿美元。经皮细分市场在分析期间的复合年增长率预计为9.0%。

美国市场规模估计为 91 亿美元，中国市场预计复合年增长率为 14.3%

美国半固态剂型CDMO市场规模预计在2024年达到91亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到125亿美元，在2024-2030年的分析期间内，复合年增长率为14.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为7.5%和9.3%。在欧洲，预计德国市场的复合年增长率约为8.3%。

全球半固态剂型 CDMO 市场－主要趋势与驱动因素摘要

为什么半固态剂量 CDMO 在药品製造上变得越来越重要？

半固态製剂合约开发与受託製造厂商(CDMO) 凭藉其在乳膏、凝胶、软膏和栓剂配製方面的专业知识，在製药业中发挥着至关重要的作用。随着製药公司将开发和生产外包给专业製造商，半固态製剂合约委託与生产组织 (CDMO) 已成为确保产品稳定性、生物利用度和合规性的关键合作伙伴。皮肤病治疗、经皮给药系统和局部止痛药的需求不断增长，进一步推动了市场的成长。此外，控制释放製剂和基于奈米技术的药物递送技术的进步也为半固态製剂合约开发与生产组织 (CDMO) 带来了更多商机。

哪些创新正在改变半固态药物 CDMO 服务？

乳化技术、微胶囊化和脂质体药物传递技术的进步正在提升半固态製剂的疗效。人工智慧预测模型正被用于优化製剂稳定性和生产可扩展性。此外，连续生产技术的采用正在提高生产效率、降低成本并最大限度地减少批次差异。个人化医疗和标靶药物递送系统的兴起也推动了患者客製化半固态製剂的开发。这些技术创新使CDMO能够提供更精准、更高品质的药物。

哪些治疗领域正在推动半固态剂量 CDMO 的成长？

由于银屑病、湿疹和痤疮等局部治疗的需求不断增长，皮肤科领域对半固态剂型CDMO的增长做出了重大贡献。随着患者寻求口服和注射药物的非侵入性治疗方法，疼痛管理和经皮给药领域也不断扩张。荷尔蒙补充疗法(HRT) 和阴道给药系统的兴起进一步促进了市场需求。此外，伤口护理和烧烫伤治疗领域正在见证具有增强癒合和抗菌特性的半固态剂型的创新。

哪些因素推动了半固态剂量 CDMO 市场的成长？

半固态剂型CDMO市场的成长动力源于製药业外包趋势的不断增长、皮肤病学和经皮治疗需求的不断增长以及製剂科学的进步。监管机构对品管和良好生产规范 (GMP) 的重视，进一步鼓励製药公司与专业的CDMO合作。此外，新兴市场的成长和非处方 (OTC) 半固态剂型的扩张也为契约製造创造了新的机会。随着製药创新的持续，半固态剂型CDMO在药物开发和製造中的作用必将日益重要。

部分

给药途径（局部、经皮等）；产品（软膏、乳霜及洗剂、糊剂、凝胶等）；服务（合约开发、受託製造）；最终用户（製药公司、生物製药公司等）

受访公司范例

• Aenova Group
• AGC Biologics
• Alcami Corporation
• Alchem Laboratories
• Almac Group
• Ascendia Pharmaceuticals
• Avid Bioservices
• Boehringer Ingelheim
• Bora Pharmaceuticals
• Cambrex Corporation
• Catalent, Inc.
• Contract Pharmaceuticals Limited
• DPT Laboratories, Ltd.
• Fermion Oy
• Hetero Labs Limited
• Hovione
• Ind-Swift Laboratories Ltd.
• LGM Pharma
• Lonza Group
• Pace Analytical Life Sciences, LLC
• Patheon NV
• Pfizer CentreOne
• Pierre Fabre Group
• Piramal Pharma Solutions
• Recipharm AB
• Rubicon Research Pvt. Ltd.
• Sharp Services
• The Lubrizol Corporation
• TriRx Pharmaceutical Services
• WuXi AppTec

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Semi-Solid Dosage CDMO Market to Reach US$60.8 Billion by 2030

The global market for Semi-Solid Dosage CDMO estimated at US$33.5 Billion in the year 2024, is expected to reach US$60.8 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 11.0% CAGR and reach US$36.5 Billion by the end of the analysis period. Growth in the Transdermal segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.1 Billion While China is Forecast to Grow at 14.3% CAGR

The Semi-Solid Dosage CDMO market in the U.S. is estimated at US$9.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$12.5 Billion by the year 2030 trailing a CAGR of 14.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Semi-Solid Dosage CDMO Market - Key Trends & Drivers Summarized

Why Are Semi-Solid Dosage CDMOs Gaining Importance In Pharmaceutical Manufacturing?

Semi-solid dosage contract development and manufacturing organizations (CDMOs) are playing a vital role in the pharmaceutical industry by providing expertise in formulating creams, gels, ointments, and suppositories. As pharmaceutical companies seek to outsource development and production to specialized manufacturers, semi-solid dosage CDMOs are becoming critical partners in ensuring product stability, bioavailability, and regulatory compliance. The rising demand for dermatological treatments, transdermal drug delivery systems, and topical pain relief products is further driving market growth. Additionally, advancements in controlled-release formulations and nanotechnology-based drug delivery are expanding the opportunities for semi-solid dosage CDMOs.

What Innovations Are Transforming Semi-Solid Dosage CDMO Services?

Advancements in emulsification technology, microencapsulation, and liposomal drug delivery are enhancing the efficacy of semi-solid pharmaceutical formulations. AI-powered predictive modeling is being used to optimize formulation stability and manufacturing scalability. Additionally, the adoption of continuous manufacturing techniques is improving production efficiency, reducing costs, and minimizing batch variability. The rise of personalized medicine and targeted drug delivery systems is also leading to the development of patient-specific semi-solid formulations. These innovations are enabling CDMOs to offer more precise, high-quality pharmaceutical products.

Which Therapeutic Areas Are Driving The Growth Of Semi-Solid Dosage CDMOs?

The dermatology sector is a major contributor to semi-solid dosage CDMO growth, with increasing demand for topical treatments for conditions such as psoriasis, eczema, and acne. The pain management and transdermal drug delivery segment is also expanding, as patients seek non-invasive alternatives to oral and injectable medications. The rise of hormone replacement therapy (HRT) and vaginal drug delivery systems is further contributing to market demand. Additionally, the wound care and burn treatment segment is driving innovation in semi-solid formulations with enhanced healing and antimicrobial properties.

What Factors Are Fueling The Growth Of The Semi-Solid Dosage CDMO Market?

The growth of the semi-solid dosage CDMO market is being driven by increasing outsourcing trends in the pharmaceutical industry, rising demand for dermatological and transdermal treatments, and advancements in formulation science. Regulatory agencies are emphasizing quality control and Good Manufacturing Practices (GMP), further encouraging pharmaceutical companies to partner with specialized CDMOs. Additionally, the growth of emerging markets and the expansion of over-the-counter (OTC) semi-solid products are creating new opportunities for contract manufacturing. As pharmaceutical innovation continues, the role of semi-solid dosage CDMOs will become increasingly essential in drug development and production.

SCOPE OF STUDY:

The report analyzes the Semi-Solid Dosage CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Topical, Transdermal, Others); Product (Ointments, Creams & Lotions, Pastes, Gels, Others); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Aenova Group
• AGC Biologics
• Alcami Corporation
• Alchem Laboratories
• Almac Group
• Ascendia Pharmaceuticals
• Avid Bioservices
• Boehringer Ingelheim
• Bora Pharmaceuticals
• Cambrex Corporation
• Catalent, Inc.
• Contract Pharmaceuticals Limited
• DPT Laboratories, Ltd.
• Fermion Oy
• Hetero Labs Limited
• Hovione
• Ind-Swift Laboratories Ltd.
• LGM Pharma
• Lonza Group
• Pace Analytical Life Sciences, LLC
• Patheon N.V.
• Pfizer CentreOne
• Pierre Fabre Group
• Piramal Pharma Solutions
• Recipharm AB
• Rubicon Research Pvt. Ltd.
• Sharp Services
• The Lubrizol Corporation
• TriRx Pharmaceutical Services
• WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Semi-Solid Dosage CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Demand for Personalized Medicine and Custom Formulations Drives Growth in Semi-Solid Dosage CDMO Services
  • Surge in Chronic Diseases and the Need for Long-Term Treatment Solutions Expands Market Opportunity for Semi-Solid Dosage Forms
  • Technological Advancements in Manufacturing Processes Propel Growth in Semi-Solid Dosage Contract Development and Manufacturing Organizations (CDMOs)
  • Rising Consumer Preference for Convenient and Easy-to-Use Topical Formulations Drives the Adoption of Semi-Solid Dosage Forms
  • Regulatory Requirements for Quality Control and Manufacturing Standards in Semi-Solid Dosages Strengthen the Business Case for CDMOs
  • The Expansion of Global Pharmaceutical Markets Increases the Demand for Semi-Solid Dosage Services in Both Emerging and Developed Markets
  • Growth of Over-the-Counter (OTC) Medications and Dermatological Treatments Expands the Addressable Market for Semi-Solid Dosage Forms
  • Rising Focus on Non-Invasive and Patient-Friendly Drug Delivery Systems Drives Demand for Semi-Solid Dosages in Various Therapeutic Areas
  • Increasing Investments in Biotechnology and Drug Development Spurs Demand for Advanced Semi-Solid Dosage CDMOs
  • Surge in Dermatology, Pain Management, and Cosmetic Markets Strengthens Demand for Semi-Solid Dosage Forms
  • Innovation in Nanotechnology and Drug Delivery Systems Expands Opportunities for Semi-Solid Dosage CDMOs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Semi-Solid Dosage CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Semi-Solid Dosage CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Semi-Solid Dosage CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Contract Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Ointments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Ointments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Ointments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Creams & Lotions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Creams & Lotions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Creams & Lotions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Pastes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Pastes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Pastes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• JAPAN
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• CHINA
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• EUROPE
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Semi-Solid Dosage CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Semi-Solid Dosage CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• FRANCE
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 107: France Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• GERMANY
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 143: UK Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• INDIA
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 218: India Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Semi-Solid Dosage CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Semi-Solid Dosage CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030
• AFRICA
  • Semi-Solid Dosage CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Semi-Solid Dosage CDMO by Administration Route - Topical, Transdermal and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Semi-Solid Dosage CDMO by Administration Route - Percentage Breakdown of Value Sales for Topical, Transdermal and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Semi-Solid Dosage CDMO by Service - Contract Manufacturing and Contract Development Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Semi-Solid Dosage CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing and Contract Development for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Semi-Solid Dosage CDMO by End-Use - Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Semi-Solid Dosage CDMO by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies, Biopharmaceutical Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Semi-Solid Dosage CDMO by Product - Ointments, Creams & Lotions, Pastes, Gels and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Semi-Solid Dosage CDMO by Product - Percentage Breakdown of Value Sales for Ointments, Creams & Lotions, Pastes, Gels and Other Products for the Years 2015, 2025 & 2030

IV. COMPETITION